The latest: Biopharmaceutical company Legend Biotech Corp. (LEGN.US) has proposed offering $300 million in American Depositary Shares (ADSs), with the option for underwriters to sell an additional $45 million worth if demand is strong.

Looking up: The new funds would provide the company with additional capital for development of drugs, construction of manufacturing facilities and for general operating purposes.

Take Note: Shares of Chinese drug makers have taken a beating this week on rumors that the U.S. Treasury Department may add more than 20 Chinese companies to its investment blacklists, including biopharmaceutical companies. Such a move could prohibit U.S. investors from buying Legend’s stock if it were blacklisted.

Digging Deeper: Legend Biotech was listed on the Nasdaq in June last year, but like many young biopharma companies has yet to turn a profit despite growing revenue. The company recorded a net loss of $303 million last year, more than double its loss the previous year. The company suffered a further loss of $298 million in the first three quarters of this year and ended the period with cash and cash equivalents of $338 million, down 25% year-on-year. The company may need more funds, which it is now trying to raise through the new share issue.

Market Reaction: Legend’s shares plunged 15.3% after the announcement to close at $41.14 on Wednesday. Its Hong Kong-listed parent, Genscript Biotech Corp (1548.HK), was also down 5% midway through the day in Asia.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Kanzhun cranks up spending, even as others tighten belts

China’s leading online recruitment platform’s operating costs soared 70% in last year’s fourth quarter, pushing the company into the red Key Takeaways: Kanzhun’s revenue was flat in the fourth quarter,…
BZ.US 2076.HK